157 related articles for article (PubMed ID: 19534693)
1. Recent developments in thrombin-activatable fibrinolysis inhibitor research.
Marx PF; Verkleij CJ; Valls Seron M; Meijers JC
Mini Rev Med Chem; 2009 Sep; 9(10):1165-73. PubMed ID: 19534693
[TBL] [Abstract][Full Text] [Related]
2. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
Bouma BN; Meijers JC
Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
[TBL] [Abstract][Full Text] [Related]
3. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
Sillen M; Declerck PJ
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916027
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).
Valnickova Z; Thaysen-Andersen M; Højrup P; Christensen T; Sanggaard KW; Kristensen T; Enghild JJ
BMC Biochem; 2009 May; 10():13. PubMed ID: 19416536
[TBL] [Abstract][Full Text] [Related]
5. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders.
Boffa MB; Nesheim ME; Koschinsky ML
Curr Drug Targets Cardiovasc Haematol Disord; 2001 Dec; 1(2):59-74. PubMed ID: 12769657
[TBL] [Abstract][Full Text] [Related]
6. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
Zhou X; Declerck PJ
J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity.
Zhao L; Buckman B; Seto M; Morser J; Nagashima M
J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375
[TBL] [Abstract][Full Text] [Related]
8. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
[TBL] [Abstract][Full Text] [Related]
9. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.
Okumura N; Koh T; Hasebe Y; Seki T; Ariga T
J Biol Chem; 2009 Jun; 284(24):16553-16561. PubMed ID: 19386599
[TBL] [Abstract][Full Text] [Related]
10. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
11. Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) is up-regulated by increase in intracellular cyclic AMP levels in cultured HepG2 cells.
Ishii H; Kojima Y; Masuda Y; Takada K; Sugimoto K; Ikeda T
Thromb Haemost; 2009 Dec; 102(6):1204-11. PubMed ID: 19967152
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
13. Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor.
Hillmayer K; Ceresa E; Vancraenenbroeck R; Declerck PJ; Gils A
J Thromb Haemost; 2008 Aug; 6(8):1426-8. PubMed ID: 18513211
[No Abstract] [Full Text] [Related]
14. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
Bouma BN; Mosnier LO
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):375-81. PubMed ID: 15692247
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor.
Marx PF
Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
[TBL] [Abstract][Full Text] [Related]
16. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
Renckens R; Roelofs JJ; ter Horst SA; van 't Veer C; Havik SR; Florquin S; Wagenaar GT; Meijers JC; van der Poll T
J Immunol; 2005 Nov; 175(10):6764-71. PubMed ID: 16272333
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
Kraft P; Schwarz T; Meijers JC; Stoll G; Kleinschnitz C
PLoS One; 2010 Jul; 5(7):e11658. PubMed ID: 20657835
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN; Marx PF; Mosnier LO; Meijers JC
Thromb Res; 2001 Mar; 101(5):329-54. PubMed ID: 11297751
[TBL] [Abstract][Full Text] [Related]
20. [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy].
Małyszko JS; Małyszko J; Hryszko T; Myśliwiec M
Pol Arch Med Wewn; 2003 Aug; 110(2):843-8. PubMed ID: 14682222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
